Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up

Here, we present an update of a phase 2 study of pembrolizumab in patients with advanced thymic carcinoma who failed previous therapies. Duration of response was approximately 3 years, and median survival was in excess of 2 years with a 5-year survival rate of 18%. The higher than expected incidence of severe autoimmune disorders (15%) did not substantially increase with a longer follow-up. Pembrolizumab induces durable responses in patients with thymic carcinoma. Careful selection of patients and monitoring of toxicities are warranted.